Metabolic Syndrome in Breast Cancer Patients: An Observational Study.

IF 1.8 Q3 ONCOLOGY

Breast Cancer : Basic and Clinical Research Pub Date : 2021-10-04 eCollection Date: 2021-01-01 DOI:10.1177/11782234211026788

Siddhant Khare, Santhosh Irrinki, Yashwant Raj Sakaray, Amanjit Bal, Tulika Singh, Gurpreet Singh

{"title":"Metabolic Syndrome in Breast Cancer Patients: An Observational Study.","authors":"Siddhant Khare, Santhosh Irrinki, Yashwant Raj Sakaray, Amanjit Bal, Tulika Singh, Gurpreet Singh","doi":"10.1177/11782234211026788","DOIUrl":null,"url":null,"abstract":"Background: The reported association between metabolic syndrome (MetS) and breast cancer may have a significant impact on the incidence and mortality related to breast cancer. We undertook this study to find if the disease is different in patients with MetS.Materials and methods: Patients with biopsy-proven breast cancer were divided into groups based on the presence or absence of MetS (according to the IDF definition of 2006) and also based on menopausal status. The presence of known risk and prognostic factors were also recorded, and the groups were compared.Results: A total of 305 patients were recruited, of which 191 (62.6%) had MetS. Patients with MetS were older than those without (52.1 versus 48.3 years, P = .014) and had a lower incidence of nulliparity (4.1% vs 12.8%, P = .005) and dense breasts (2.9% in MetS vs 10.8% in no MetS, P = .009). On further dividing into premenopausal and postmenopausal, these differences persisted only in premenopausal patients. MetS group had a lower number of HER2-positive tumours (14.3% for MetS, 23.9% for no MetS; P = .036). After dividing into premenopausal and postmenopausal, significant differences were observed in distant metastases (5.4% in MetS vs 16.1% in no MetS, P = .045) and in grade (higher grade in MetS, P = .05) in premenopausal patients. In postmenopausal patients, difference was observed in HER2 positivity (12.3% in MetS vs 28.8% in no MetS, P = .008).Conclusions: Breast cancer in patients with MetS may not be significantly different from breast cancer in patients without MetS.","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"15 ","pages":"11782234211026788"},"PeriodicalIF":1.8000,"publicationDate":"2021-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/ba/10.1177_11782234211026788.PMC8493313.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer : Basic and Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11782234211026788","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The reported association between metabolic syndrome (MetS) and breast cancer may have a significant impact on the incidence and mortality related to breast cancer. We undertook this study to find if the disease is different in patients with MetS.

Materials and methods: Patients with biopsy-proven breast cancer were divided into groups based on the presence or absence of MetS (according to the IDF definition of 2006) and also based on menopausal status. The presence of known risk and prognostic factors were also recorded, and the groups were compared.

Results: A total of 305 patients were recruited, of which 191 (62.6%) had MetS. Patients with MetS were older than those without (52.1 versus 48.3 years, P = .014) and had a lower incidence of nulliparity (4.1% vs 12.8%, P = .005) and dense breasts (2.9% in MetS vs 10.8% in no MetS, P = .009). On further dividing into premenopausal and postmenopausal, these differences persisted only in premenopausal patients. MetS group had a lower number of HER2-positive tumours (14.3% for MetS, 23.9% for no MetS; P = .036). After dividing into premenopausal and postmenopausal, significant differences were observed in distant metastases (5.4% in MetS vs 16.1% in no MetS, P = .045) and in grade (higher grade in MetS, P = .05) in premenopausal patients. In postmenopausal patients, difference was observed in HER2 positivity (12.3% in MetS vs 28.8% in no MetS, P = .008).

Conclusions: Breast cancer in patients with MetS may not be significantly different from breast cancer in patients without MetS.

Abstract Image

查看原文本刊更多论文

乳腺癌患者的代谢综合征:一项观察性研究

背景:已报道的代谢综合征(MetS)与乳腺癌之间的关联可能对乳腺癌相关的发病率和死亡率产生重大影响。我们进行这项研究是为了发现met患者的疾病是否不同。材料和方法:活检证实的乳腺癌患者根据有无MetS(根据2006年IDF的定义)和绝经状态分为两组。记录已知危险因素和预后因素的存在，并对两组进行比较。结果:共招募了305例患者，其中191例(62.6%)患有MetS。有肿瘤转移的患者比没有肿瘤转移的患者年龄更大(52.1岁对48.3岁，P = 0.014)，无产发生率(4.1%对12.8%，P = 0.005)和致密乳房发生率(2.9%对10.8%，P = 0.009)更低。进一步分为绝经前和绝经后，这些差异只存在于绝经前患者。MetS组her2阳性肿瘤的数量较低(MetS为14.3%，无MetS为23.9%;p = .036)。在将绝经前和绝经后患者分为两组后，观察到绝经前患者的远处转移(MetS患者为5.4%，无MetS患者为16.1%，P = 0.045)和分级(MetS患者级别较高，P = 0.05)有显著差异。在绝经后患者中，观察到HER2阳性的差异(MetS组为12.3%，非MetS组为28.8%，P = 0.008)。结论:met患者的乳腺癌与非met患者的乳腺癌可能没有显著差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer : Basic and Clinical Research ONCOLOGY-

CiteScore

5.10

自引率

3.40%

发文量

审稿时长

8 weeks

期刊介绍： Breast Cancer: Basic and Clinical Research is an international, open access, peer-reviewed, journal which considers manuscripts on all areas of breast cancer research and treatment. We welcome original research, short notes, case studies and review articles related to breast cancer-related research. Specific areas of interest include, but are not limited to, breast cancer sub types, pathobiology, metastasis, genetics and epigenetics, mammary gland biology, breast cancer models, prevention, detection, therapy and clinical interventions, and epidemiology and population genetics.